Genetic Technologies Limited (GTG.AX)
| Previous close | 0.0070 |
| Open | 0.0070 |
| Bid | 0.0070 x 10000000 |
| Ask | 0.0080 x 249000000 |
| Day's range | 0.0070 - 0.0070 |
| 52-week range | 0.0060 - 0.0140 |
| Volume | 45,593,383 |
| Avg. volume | 2,504,804 |
| Market cap | 64.583M |
| Beta (5Y monthly) | 0.91 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0010 |
| Earnings date | 30 Aug 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 0.25 |
- GlobeNewswire
GENE Delivers Material 12-Fold Increase in Revenue in the Quarter Ended September 2021
Commercialisation plans gather momentumMELBOURNE, Australia, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease, announces a 12-fold increase in revenue generated during the September 2021 quarter to A$850k1. Highlights: Delivering a material 12-fold increase in customer receipts to A$850k, versus June 2021 quarterRevenue primarily derived from license and resa
- GlobeNewswire
Genetic Technologies Limited Interview to Air on Bloomberg TV (U.S.) on the RedChip Money Report®
MELBOURNE, Australia, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in Genomics based tests in health, wellness and serious disease, today announced that an interview with CEO Simon Morriss, discussing the advancements on their commercialization plans, the recent acquisition of EasyDNA and the associated near term material revenue increase, will air on The RedChip Money Report® on Bloomberg TV (U.S.), Saturday, October
- GlobeNewswire
GENE Embarks on Breakthrough African American Collaboration for Breast Cancer as Part of Its Commitment to Ethnic Diversity
Study to focus on women of African American descent for expanded polygenic risk testMELBOURNE, Australia, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a diversified Genomics and AI driven preventative health business today announced that they have entered into a strategic collaboration with the Institute of Public Health in St Louis USA for the purpose of expanding the predictive capabilities of the GeneType for Breast Cancer product
